Sumary of New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern:
- Simultaneously, however, new strains are emerging that show resistance to antibodies elicited by earlier strains, and/or increased transmissibility..
- All VOCs identified so far contain the D614G mutation that increases infectivity, possibly by increasing the expression of the spike protein on the surface of the viral particle..
- The L452R mutation is present in B.1.429 (Epsilon), B.1.617.1 and B.1.617.2, reducing susceptibility to neutralizing antibodies..
- E484K in both B.1.351 and P.1 isolates may increase spike-receptor binding as well as conferring antibody escape capability..
- This variant contains N501Y and 484K, among other mutations in the spike protein, of which three are thought to enhance spike-receptor binding affinity..
- The B.1.351 variant was first reported in October 2021, with three RBD mutations that increase spike-RBD binding and thus impaired neutralizing capacity..
- Adenovirus-vectored and mRNA-based vaccines are easily tailored to incorporate mutated spike antigens to meet the challenges posed by newer variants..
- Single-dose of AZD2816 produces cross-reactive immunity In the current experiment, the researchers found that a single dose of either the new vaccine or the original ChAdOx1 nCoV-19 (AZD1222) vaccine produced a robust antibody response….